Silver Book Fact
According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers. The medicine, a monoclonal antibody, would stimulate the immune system to attack the protein–killing the tumors.
Alzheimer's Association. Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research. Falls Church, VA: The Lewin Group; 2004